{"doi":"10.1093/annonc/mdt276","title":"First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients","abstract":null,"journal":"Annals of Oncology","year":2013,"id":633670,"datarank":0.8150583005331361,"base_score":5.43372200355424,"endowment":5.43372200355424,"self_citation_contribution":0.8150583005331361,"citation_network_contribution":0.0,"self_endowment_contribution":0.8150583005331361,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":228,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1643044,"name":"V. Diéras","orcid":null,"position":1,"is_corresponding":false},{"id":834722,"name":"J. Cortés","orcid":null,"position":2,"is_corresponding":false},{"id":1643045,"name":"A.-A. Duenne","orcid":null,"position":3,"is_corresponding":false},{"id":579757,"name":"J. Yi","orcid":null,"position":4,"is_corresponding":false},{"id":1643046,"name":"J. O'Shaughnessy","orcid":null,"position":5,"is_corresponding":false},{"id":1571367,"name":"D.W. Miles","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients","abstract":"<h4>Background</h4>Bevacizumab has consistently demonstrated improved progression-free survival (PFS) and response rate when combined with first-line chemotherapy for HER2-negative metastatic breast cancer (mBC). However, the lack of a significant overall survival (OS) difference continues to attract debate, and identification of patients deriving greatest benefit from bevacizumab remains elusive.<h4>Patients and methods</h4>Individual patient data from three randomised phase III trials in the first-line HER2-negative mBC setting were analysed, focusing specifically on efficacy in poor-prognosis patients.<h4>Results</h4>The meta-analysis (n = 2447) demonstrated a PFS hazard ratio (HR) of 0.64 (95% confidence interval [CI] 0.57-0.71; median 9.2 months with bevacizumab versus 6.7 months with non-bevacizumab therapy) and response rate of 49% versus 32%, respectively. The OS HR was 0.97 (95% CI 0.86-1.08); median 26.7 versus 26.4 months, respectively. In patients with triple-negative mBC, the HRs for PFS and OS were 0.63 (95% CI 0.52-0.76) and 0.96 (95% CI 0.79-1.16), respectively. Median PFS was 8.1 months with bevacizumab versus 5.4 months with chemotherapy alone, median OS was 18.9 versus 17.5 months, respectively, and 1-year OS rates were 71% versus 65%.<h4>Conclusions</h4>Bevacizumab improves efficacy, including 1-year OS rates, both overall and in subgroups of poor-prognosis patients with limited treatment options.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23894038","pmcid":null,"openalex_id":null,"authors":[],"funders":[{"funder_name":"F. Hoffmann-La Roche Ltd","grant_id":"","title":null}],"total_grants":1,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":"http://www.elsevier.com/open-access/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0923753419373466?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0923753419373466?httpAccept=text/plain","host_type":"publisher"},{"url":"http://academic.oup.com/annonc/article-pdf/24/11/2773/16700635/mdt276.pdf","host_type":"publisher"}],"fields_of_study":[],"mesh_terms":["Humans","Breast Neoplasms","Neoplasm Metastasis","Neovascularization, Pathologic","Vascular Endothelial Growth Factor A","Disease-Free Survival","Female","Randomized Controlled Trials as Topic","Kaplan-Meier Estimate","Antibodies, Monoclonal, Humanized","Bevacizumab","Erb-b2 Receptor Tyrosine Kinases"],"keywords":["Anti-angiogenesis","Metastatic breast cancer","Vascular Endothelial Growth Factor","Bevacizumab","First-line Therapy","Triple-negative Breast Cancer"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T12:27:52.517533Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}